Ex vivo tumor derived organoid pharmacotyping identifies personalized therapeutic options for biliary tract cancer patients.

Annie Blair Richardson¹, Payel Chatterjee¹, Rachele Rosati¹, Alex Rajewski², Robert L Diaz¹, Lauren R Appleyard¹, Shalini Pereira¹, Brady Bernard³, Milind M Javle⁴, Gentry G King⁵, Adam Diehl⁵, William Proctor Harris⁵, Sameek Roychowdhury⁶, Christopher J Kemp⁷, Carla Grandori¹

¹Cure First Bothell, WA United States.

²Tempus AI Bothell, WA United States.

³Providence Cancer Institute Portland, OR United States.

⁴The University of Texas MD Anderson Cancer Center Houston, TX United States.

⁵University of Washington Seattle, WA United States.

⁶The Ohio State University Columbus, OH United States.

⁷Fred Hutch Cancer Center DC, WA United States.

PubMed DOI

Abstract

Biliary tract cancers (BTCs) pose clinical challenges due to poor chemotherapy response and aggressive disease course. We evaluated patient derived tumor organoid (PDTO) based drug sensitivity testing as a tool to guide therapy. In this multicenter study, 26 tumor organoids were successfully derived from 43 BTC patients and tested with an average of 50 cancer-directed therapies using the CLIA cert…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.